Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
出版年份 2021 全文链接
标题
Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
作者
关键词
-
出版物
BMJ-British Medical Journal
Volume -, Issue -, Pages n156
出版商
BMJ
发表日期
2021-02-25
DOI
10.1136/bmj.n156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future
- (2018) Jeffrey Cummings et al. JOURNAL OF ALZHEIMERS DISEASE
- Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
- (2018) Julia R. Clarke et al. JOURNAL OF ALZHEIMERS DISEASE
- Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
- (2018) Pierrick Bourgeat et al. NEUROIMAGE
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
- (2015) Steve Balsis et al. CLINICAL NEUROPSYCHOLOGIST
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Instrumental variable methods for causal inference
- (2014) Michael Baiocchi et al. STATISTICS IN MEDICINE
- Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
- (2014) Lars Lannfelt et al. Alzheimers Research & Therapy
- Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
- (2012) Kevin Mullane et al. BIOCHEMICAL PHARMACOLOGY
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
- (2012) Bruno P Imbimbo et al. Expert Review of Clinical Immunology
- Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
- (2012) Peter T. Nelson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Resolving controversies on the path to Alzheimer's therapeutics
- (2011) Dennis J Selkoe NATURE MEDICINE
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- PET imaging of amyloid deposition in patients with mild cognitive impairment
- (2007) Anton Forsberg et al. NEUROBIOLOGY OF AGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation